Find participating medical centers and current study status in each of them

    Find participating medical centers

    A phase I, open-label, single-dose study to evaluate the effect of mild or moderate hepatic impairment on the pharmacokinetics of fenebrutinib

    • Autoimmune Disorder
    • Multiple Sclerosis (MS)
    • Metabolic Disorder
    • Impaired hepatic function